Somapacitan is in clinical development for the treatment of small for gestational age or Noonan syndrome or idiopathic short stature in patients aged 2 to 18 years. Idiopathic short stature is defined as shortness in childhood without a specific cause. This condition may be familial (run in families) or nonfamilial and may be associated with or without delay of puberty. Noonan syndrome is a genetic condition that can cause a wide range of distinctive features and health problems, including short stature. Small for gestational age describes newborn babies with a birth weight and/or length below the normal range for gestational age. Current treatment for growth disturbance in Noonan syndrome or children born small for gestational age whose growth has not caught up by 4 years or later involves daily growth hormone injections that can be burdensome for patients and caregivers. There is no approved growth hormone for idiopathic short stature.
Somapacitan for treating idiopathic short stature or Noonan syndrome or small for gestational age in people aged 2 to 18 years
Somapacitan is in clinical development for the treatment of small for gestational age or Noonan syndrome or idiopathic short stature in patients aged 2 to 18 years. Idiopathic short stature is defined as shortness in childhood without a specific cause.